Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
|
|
Organogenesis Holdings Inc. (AHPA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/01/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/15/2022 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events Interactive Data |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/18/2022 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors CANTON, Mass., February 17, 2022 — Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Michael J. Driscoll, Ed.D. to the Company's Board of Directors, effective February 15, 2022. Dr. Driscoll will serve as an independent director of the Company and member of the Audit Committee and the Nominating Committee of the Board. “I am pleased to welcome Dr. Driscoll to our Board of Directors following a 28-year career in the financial services industry, as well as 10 years in academia as a business school professor and dean.”..." |
|
| 12/30/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/22/2021 |
8-K
| Appointed a new director|
Docs:
|
"Organogenesis Appoints Prathyusha Duraibabu to Board of Directors CANTON, Mass., November 22, 2021 — Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. “Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positions at global biotechnology and life sciences companies.” said Ga..." |
|
| 11/09/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/16/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
8-K
| Quarterly results |
| 05/27/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K/A
| Quarterly results |
| 05/10/2021 |
8-K
| Quarterly results |
| 04/02/2021 |
8-K
| Quarterly results |
| 03/16/2021 |
8-K
| Quarterly results |
| 02/16/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 16, 2021 ORGANOGENESIS HOLDINGS INC. Delaware 001-37906 98-1329150 85 Dan Road Canton, MA 02021 575-0775 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exc...",
"Offer Letter between Organogenesis Holdings Inc. and David C. Francisco",
"Organogenesis Appoints David C. Francisco as Chief Financial Officer CANTON, Mass., February 16, 2021 — Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of David C. Francisco as the Company's Chief Financial Officer, effective February 15, 2021. In connection with the hiring of Mr. Francisco, Henry Hagopian will serve as the Company's Senior Vice President of Finance and Treasurer. “I am pleased to welcome Dave to the Organogenesis executive leadership team,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. Dave brings strong strategic, financial, and operat..." |
|
| 01/13/2021 |
8-K
| Quarterly results |
| 12/18/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 12/10/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/18/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/09/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 11/03/2020 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 |
| 10/14/2020 |
8-K
| Quarterly results |
| 09/15/2020 |
8-K
| Investor presentation |
| 08/24/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 07/20/2020 |
8-K
| Quarterly results |
|
|
|